Short-Term Debt to Equity Ratio: Neurocrine Biosciences (NBIX)
By leveraging steady demand in neuromedicine and effective drug launch management, Neurocrine Biosciences (NBIX) minimizes external risks. The shift in the short interest-to-equity ratio confirms this stability, with the value holding at 0.01. The scaling of flagship products is currently creating powerful operating leverage, allowing the company to easily cover R&D costs and expand overall margins.
neurocrine.com (NBIX) - metric breakdowns and financial figures
- stock quotes and analyst forecast:
- company stock exchange capitalization indicators:
- issuer book value statistics:
- company liabilities and liquidity data:
Debt to Equity Neurocrine Biosciences|NBIX - Long-Term Debt to Capital Ratio|Short-Term Debt to Capital Neurocrine Biosciences, Inc.|NBIX - Company Cumulative Debt|Debt to Book Value Neurocrine|NBIX - Company Long-Term Debts|Company Short-Term Debt Neurocrine Biosciences|Quick Liquidity neurocrine.com
- company profitability and valuation multiples indicators:
Analysis of all company metrics:Neurocrine Biosciences Inc NBIX
The ratio is calculated as the proportion of liabilities with a maturity exceeding one year to total equity. This metric determines the extent to which financial stability depends on long-term borrowings within the balance sheet structure. For Neurocrine Biosciences (NBIX), such resources are critical for financing costly neurobiological research. This chart of the company's short-term debt-to-equity dynamics allows for an assessment of the balance between investment risk and growth potential.
Analysis of competing companies
Short-Term Debt to Capital BIIB|RGC - Current Liabilities to Capital|Axsome Therapeutics - Short-Term Debt to Equity Ratio|Short-Term Debt to Capital acadia-pharm.com ACAD|XENE - Short-Term Debt to Equity|Ratio of Short-Term Indebtedness to Capital VKTX (Viking Therapeutics Inc)|Supernus Pharma (SUPN) - Short-Term Debt to Equity|Current Liabilities to Capital Catalyst Corp (CPRX)|Short-Term Debt to Equity Denali Therapeutics|Short-Term Debt to Capital Ratio HRMY (harmonybiosciences.com)|Short-Term Debt to Capital BHVN|AMLX - Current Liabilities to Capital|Trevi Pharma - Short-Term Debt to Equity Ratio|Short-Term Debt to Capital Praxis Corp PRAX|AVXL - Short-Term Debt to Equity|Ratio of Short-Term Indebtedness to Capital CBLL (ceribell.com)|Prothena Corp (PRTA) - Short-Term Debt to Equity|Current Liabilities to Capital Alector (ALEC)|ANNX (Annexon Inc.) - Short-Term Debt to Capital|Short-Term Debt to Equity Ratio Omeros Corp. (OMER)|Short-Term Debt to Equity Neurogene Inc. (NGNE)|ACIU (acimmune.com) - Ratio of Short-Term Indebtedness to Capital|Short-Term Debt to Capital VYGR (Voyager Therapeutics, Inc.)|Short-Term Debt to Capital Coefficient Neumora (NMRA)|SCLX - Short-Term Debt to Equity|TVGN (Tevogen Bio Inc.) - Short-Term Debt to Capital Ratio|ACOG: Short-Term Debt to Capital|Current Liabilities to Capital cogrx.com (CGTX)|Short-Term Debt to Equity Ratio IKT|SAVA: Ratio of Short-Term Indebtedness to Capital|Short-Term Debt to Capital ASRT|Short-Term Debt to Equity COYA (coyatherapeutics.com)|Short-Term Debt to Capital VTGN (Vistagen)|Short-Term Debt to Capital Coefficient Ovid Therapeutics Inc (OVID)|ABOS - Short-Term Debt to Equity|Current Liabilities to Capital CervoMed, Inc.|alteritytherapeutics.com (ATHE) - Short-Term Debt to Equity|CLNN - Short-Term Debt to Capital Coefficient|PEPG (PepGen Inc) - Short-Term Debt to Capital|Short-Term Debt to Equity Ratio jupiterneurosciences.com (JUNS)|Short-Term Debt to Capital RLMD|Short-Term Debt to Capital Coefficient Annovis Bio Inc|Short-Term Debt to Capital GRCE (Grace Therapeutics)|Firefly Neuro (AIFF) - Current Liabilities to Capital|KLTO - Short-Term Debt to Equity|NRSN (NeuroSense Therapeutics) - Short-Term Debt to Capital Ratio|RVPH: Short-Term Debt to Capital|Short-Term Debt to Equity Ratio MetaVia|NRXS (NeurAxis, Inc) - Short-Term Debt to Capital|Current Liabilities to Capital Helius Medical Technologies Inc. HSDT|Short-Term Debt to Equity Passage Bio, Inc. (PASG)|Short-Term Debt to Capital Coefficient bionomics.com.au|Short-Term Debt to Equity Minerva Neurosciences, Inc. NERV|ATHA: Short-Term Debt to Capital Ratio|Addex Therapeutics, Ltd. - Short-Term Debt to Capital|ALZN: Short-Term Debt to Equity|CYCN: Short-Term Debt to Capital|PTIX - Short-Term Debt to Capital Coefficient|Short-Term Debt to Equity Ratio KTTA|Short-Term Debt to Capital Ratio CRGT (Cortigent Medical)|Short-Term Debt to Equity Avenue Therapeutics, Inc (ATXI)|BrainStorm Cell Therapeutics Inc. - Short-Term Debt to Capital Ratio|Short-Term Debt to Capital CARA (Cara Therapeutics, Inc.)|chromocell.com (CHRO) - Current Liabilities to Capital|ELYM: Short-Term Debt to Equity Ratio|ITCI - Short-Term Debt to Capital|Longboard Pharma (LBPH) - Short-Term Debt to Equity|Marinus Pharma - Ratio of Short-Term Indebtedness to Capital|Short-Term Debt to Equity NKGen Biotech, Inc.|Current Liabilities to Capital neurobopharma.com NRBO|Short-Term Debt to Equity Sage Therapeutics (SAGE)|Synaptogenix Inc. - Short-Term Debt to Capital Ratio|Short-Term Debt to Capital TRVN (Trevena, Inc)|Vigil Neuroscience Inc. (VIGL) - Current Liabilities to Capital|WENA: Short-Term Debt to Equity Ratio|CERE - Short-Term Debt to Capital